BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36108252)

  • 21. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
    Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.
    Leahy AB; Devine KJ; Li Y; Liu H; Myers R; DiNofia A; Wray L; Rheingold SR; Callahan C; Baniewicz D; Patino M; Newman H; Hunger SP; Grupp SA; Barrett DM; Maude SL
    Blood; 2022 Apr; 139(14):2173-2185. PubMed ID: 34871373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Long-term safety and activity of humanized CD19 chimeric antigen receptor T cells for children and young adults with relapsed/refractory acute lymphoblastic leukemia].
    Wang SY; Zhao LN; Cheng H; Shi M; Chen W; Qi KM; Sun C; Wang X; Cao J; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):557-561. PubMed ID: 36709132
    [No Abstract]   [Full Text] [Related]  

  • 24. Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.
    Laetsch TW; Maude SL; Balduzzi A; Rives S; Bittencourt H; Boyer MW; Buechner J; De Moerloose B; Qayed M; Phillips CL; Pulsipher MA; Hiramatsu H; Tiwari R; Grupp SA
    Leukemia; 2022 Jun; 36(6):1508-1515. PubMed ID: 35422096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia.
    Myers RM; Jacoby E; Pulsipher MA; Pasquini MC; Grupp SA; Shah NN; Laetsch TW; Curran KJ; Schultz LM
    Transplant Cell Ther; 2023 Oct; 29(10):598-607. PubMed ID: 37481241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
    Gupta S; Kohorst M; Alkhateeb HB
    Eur J Haematol; 2024 Jan; 112(1):51-63. PubMed ID: 38105391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.
    Holland EM; Yates B; Steinberg SM; Yuan CM; Wang HW; Annesley C; Shalabi H; Stroncek D; Fry TJ; Krueger J; Jacoby E; Hsieh E; Bhojwani D; Gardner RA; Maude SL; Shah NN
    Transplant Cell Ther; 2023 Sep; 29(9):574.e1-574.e10. PubMed ID: 37394115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
    Mueller KT; Waldron E; Grupp SA; Levine JE; Laetsch TW; Pulsipher MA; Boyer MW; August KJ; Hamilton J; Awasthi R; Stein AM; Sickert D; Chakraborty A; Levine BL; June CH; Tomassian L; Shah SS; Leung M; Taran T; Wood PA; Maude SL
    Clin Cancer Res; 2018 Dec; 24(24):6175-6184. PubMed ID: 30190371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
    Du MY; Zhang YQ; Liao DY; Xie W; Xiong W; Mei H; Hu Y
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):793-799. PubMed ID: 38049329
    [No Abstract]   [Full Text] [Related]  

  • 30. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
    Moskop A; Pommert L; Baggott C; Prabhu S; Pacenta HL; Phillips CL; Rossoff J; Stefanski HE; Talano JA; Margossian SP; Verneris MR; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston ML; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Chinnabhandar V; Goksenin AY; Curran KJ; Mackall CL; Laetsch TW; Guest EM; Breese EH; Schultz LM
    Blood Adv; 2022 Jul; 6(14):4251-4255. PubMed ID: 35580324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel.
    Galletta TJ; Rubinstein JD; Krupski C; Nelson AS; Khoury R; Dandoy CE; Davies SM; Phillips CL
    Pediatr Blood Cancer; 2023 May; 70(5):e30271. PubMed ID: 36815392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
    Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
    JAMA Pediatr; 2018 Dec; 172(12):1161-1168. PubMed ID: 30304407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
    Maude SL; Laetsch TW; Buechner J; Rives S; Boyer M; Bittencourt H; Bader P; Verneris MR; Stefanski HE; Myers GD; Qayed M; De Moerloose B; Hiramatsu H; Schlis K; Davis KL; Martin PL; Nemecek ER; Yanik GA; Peters C; Baruchel A; Boissel N; Mechinaud F; Balduzzi A; Krueger J; June CH; Levine BL; Wood P; Taran T; Leung M; Mueller KT; Zhang Y; Sen K; Lebwohl D; Pulsipher MA; Grupp SA
    N Engl J Med; 2018 Feb; 378(5):439-448. PubMed ID: 29385370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.
    Liu Y; Chen X; Han W; Zhang Y
    Drugs Today (Barc); 2017 Nov; 53(11):597-608. PubMed ID: 29451276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
    Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
    Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
    Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X
    Front Immunol; 2022; 13():879030. PubMed ID: 35558072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Pasquini MC; Hu ZH; Curran K; Laetsch T; Locke F; Rouce R; Pulsipher MA; Phillips CL; Keating A; Frigault MJ; Salzberg D; Jaglowski S; Sasine JP; Rosenthal J; Ghosh M; Landsburg D; Margossian S; Martin PL; Kamdar MK; Hematti P; Nikiforow S; Turtle C; Perales MA; Steinert P; Horowitz MM; Moskop A; Pacaud L; Yi L; Chawla R; Bleickardt E; Grupp S
    Blood Adv; 2020 Nov; 4(21):5414-5424. PubMed ID: 33147337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.
    Ghorashian S; Jacoby E; De Moerloose B; Rives S; Bonney D; Shenton G; Bader P; Bodmer N; Quintana AM; Herrero B; Algeri M; Locatelli F; Vettenranta K; Gonzalez B; Attarbaschi A; Harris S; Bourquin JP; Baruchel A
    Lancet Haematol; 2022 Oct; 9(10):e766-e775. PubMed ID: 36084658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.